Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 09:05:29 11/07/2025 pm IST			Pre-market 11:45:36 am
7.046 ^EUR	-2.14%		7.000	-0.65%

09/07	EVOTEC : Deutsche Bank reiterates its Neutral rating	ZD
26/06	EVOTEC : Warburg Research remains its Buy rating	ZD

Evotec very weak after quarterly figures

Published on 06/05/2025 at 12:19

FRANKFURT (dpa-AFX Broker) - Evotec shares slipped significantly on Tuesday after reporting its business figures. A trader commented that the first quarter had been worse than expected. The drug discovery company's shares lost more than 7 percent on Tradegate to below 7 euros compared to the Xetra closing price.

The share price recovery had recently stalled around the €7.70 mark since the low point at the beginning of April. With the current decline, the shares on Xetra are now likely to break through the 200-day line for the longer-term trend.

The 50-day line for the medium-term trend could also be at risk. The shares are well supported at around 5 euros. /ajx/zb

-----------------------

dpa-AFX Broker – trader news from dpa-AFX

-----------------------

Go to the original article.
Legal disclaimer

Latest news about Evotec SE

EVOTEC : Deutsche Bank reiterates its Neutral rating	09/07	ZD
EVOTEC : Warburg Research remains its Buy rating	26/06	ZD
Sector Update: Health Care Stocks Mixed Premarket Wednesday	25/06	MT
Evotec Joins Acute Kidney Injury Consortium	25/06	MT
Evotec SE Joins the NURTuRE-AKI Consortium for Establishing Patient Cohort for Establishing A Patient Cohort for Establishing a Patient Cohort for Acute Kidney Injury	25/06	CI
Evotec SE, Q1 2025 Earnings Call, May 06, 2025	20/06
EVOTEC : Warburg Research reiterates its Buy rating	17/06	ZD
Evotec SE Approves Board Appointments	03/06	CI
Evotec corrects recent rise – chart uninspiring	27/05	DP
Evotec recovers to March level	23/05	DP
EVOTEC : RBC reiterates its Buy rating	15/05	ZD
Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins and Advance Small-Molecule Therapeutics at Scale	08/05	CI
EVOTEC : Deutsche Bank gives a Neutral rating	07/05	ZD
Evotec Secures New Grant to Develop Tuberculosis Treatments	07/05	MT
Evotec Receives $2.5 Mln Grant For Tb Treatments	07/05	RE
EVOTEC : Warburg Research keeps its Buy rating	06/05	ZD
Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2025	06/05	CI
Evotec starts the year with a decline in sales – shares lose significant ground	06/05	DP
RBC leaves Evotec at 'Outperform' - target €11.60	06/05	DP
Evotec very weak after quarterly figures	06/05	DP
EVOTEC : Receives a Buy rating from RBC	06/05	ZD
Evotec Outlook FY Revenue EUR 840-880 Million	06/05	RE
Evotec's Ongoing Bristol Myers Collaboration Triggers $75 Million Payments	24/04	MT
Evotec recovery stalls despite success in research alliance	24/04	DP
Evotec Announces Progress In Protein Degradation Collaboration With Bristol Myers Squibb	24/04	RE

Chart Evotec SE

Duration

Period

EVT: Dynamic Chart

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees

4,766

Sector

Biotechnology & Medical Research

Calendar

13/08 - Q2 2025 Earnings Call

More about the company